These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10882302)

  • 21. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 22. [Tyrosine kinases. New target of anticancer therapy].
    Majsterek I; Pytel D; Błasiak J
    Postepy Biochem; 2005; 51(3):251-60. PubMed ID: 16381169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.
    Jung YD; Mansfield PF; Akagi M; Takeda A; Liu W; Bucana CD; Hicklin DJ; Ellis LM
    Eur J Cancer; 2002 May; 38(8):1133-40. PubMed ID: 12008203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of new targeted therapies for breast cancer.
    Doyle DM; Miller KD
    Cancer Treat Res; 2008; 141():119-34. PubMed ID: 18274086
    [No Abstract]   [Full Text] [Related]  

  • 28. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Targeted therapies in breast cancer].
    Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
    Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer.
    Singla H; Munshi A; Banipal RPS; Kumar V
    Curr Cancer Drug Targets; 2018; 18(4):306-327. PubMed ID: 28669349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
    Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
    Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
    Camirand A; Lu Y; Pollak M
    Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
    Arteaga CL
    J Clin Oncol; 2006 Aug; 24(23):3722-5. PubMed ID: 16847283
    [No Abstract]   [Full Text] [Related]  

  • 37. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
    Awada A; Bozovic-Spasojevic I; Chow L
    Cancer Treat Rev; 2012 Aug; 38(5):494-504. PubMed ID: 22305205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives on anti-HER monoclonal antibodies.
    Ranson M; Sliwkowski MX
    Oncology; 2002; 63 Suppl 1():17-24. PubMed ID: 12422051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.